Alimera Sciences Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 158

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $358M

  • Investors
  • 4

Alimera Sciences General Information

Description

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.

Contact Information

Website
www.alimerasciences.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 6310 Town Square
  • Suite 400
  • Alpharetta, GA 30005
  • United States
+1 (678)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Acquirer
ANI Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • 6310 Town Square
  • Suite 400
  • Alpharetta, GA 30005
  • United States
+1 (678)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alimera Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
23. Merger/Acquisition 16-Sep-2024 $358M Completed Generating Revenue/Not Profitable
22. Debt Refinancing 28-Mar-2023 Completed Generating Revenue/Not Profitable
21. PIPE 18-May-2023 Completed Generating Revenue/Not Profitable
20. PIPE 24-Mar-2023 Completed Generating Revenue/Not Profitable
19. Secondary Transaction - Open Market Completed Generating Revenue/Not Profitable
18. Debt Refinancing 06-Jan-2020 Completed Generating Revenue/Not Profitable
17. Debt Refinancing 11-Jan-2018 Completed Generating Revenue/Not Profitable
16. Secondary Transaction - Open Market Completed Generating Revenue/Not Profitable
15. General Corporate Purpose 24-Oct-2016 $35M $385M Completed Generating Revenue/Not Profitable
14. 2PO 11-Aug-2016 $25.2M $385M Completed Generating Revenue/Not Profitable
To view Alimera Sciences’s complete valuation and funding history, request access »

Alimera Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatme
Pharmaceuticals
Alpharetta, GA
158 As of 2022

Rahway, NJ
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alimera Sciences Competitors (33)

One of Alimera Sciences’s 33 competitors is Merck & Co., a Corporation company based in Rahway, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Merck & Co. Corporation Rahway, NJ
AVEO Oncology Formerly VC-backed Boston, MA
EyePoint Pharmaceuticals Corporation Watertown, MA
Achaogen Formerly VC-backed South San Francisco, CA
Exonate Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 33 competitors. Get the full list »

Alimera Sciences Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Alimera Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3787749-A1 Methods of treating retinal diseases Pending 03-May-2018
US-11400070-B2 Methods of treating retinal diseases Active 03-May-2018
US-20190336466-A1 Methods of treating retinal diseases Active 03-May-2018
EP-3787749-A4 Methods of treating retinal diseases Pending 03-May-2018
US-20110150967-A1 Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids Active 23-Dec-2009 A61K9/0051
To view Alimera Sciences’s complete patent history, request access »

Alimera Sciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alimera Sciences Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Croft & Bender Investment Bank Minority
Deerfield Management Venture Capital Minority
Domain Associates Venture Capital Minority
Growth Equity Opportunities Fund Growth/Expansion Minority
HBM Healthcare Investments Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Alimera Sciences Investments (1)

Alimera Sciences’s most recent deal was a Corporate Asset Purchase with Alimera Sciences (YUTIQ RIGHTS) for . The deal was made on 19-May-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Alimera Sciences (YUTIQ RIGHTS) 19-May-2023 Corporate Asset Purchase Buildings and Property
To view Alimera Sciences’s complete investments history, request access »

Ready to get started?

Request a free trial

Alimera Sciences ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Alimera Sciences’s complete esg history, request access »

Alimera Sciences FAQs

  • When was Alimera Sciences founded?

    Alimera Sciences was founded in 2003.

  • Where is Alimera Sciences headquartered?

    Alimera Sciences is headquartered in Alpharetta, GA.

  • What is the size of Alimera Sciences?

    Alimera Sciences has 158 total employees.

  • What industry is Alimera Sciences in?

    Alimera Sciences’s primary industry is Pharmaceuticals.

  • Is Alimera Sciences a private or public company?

    Alimera Sciences is a Private company.

  • What is the current valuation of Alimera Sciences?

    The current valuation of Alimera Sciences is .

  • What is Alimera Sciences’s current revenue?

    The current revenue for Alimera Sciences is .

  • How much funding has Alimera Sciences raised over time?

    Alimera Sciences has raised $554M.

  • Who are Alimera Sciences’s investors?

    Croft & Bender, Deerfield Management, Domain Associates, Growth Equity Opportunities Fund, and HBM Healthcare Investments are 5 of 11 investors who have invested in Alimera Sciences.

  • Who are Alimera Sciences’s competitors?

    Merck & Co., AVEO Oncology, EyePoint Pharmaceuticals, Achaogen, and Exonate are some of the 33 competitors of Alimera Sciences.

  • When was Alimera Sciences acquired?

    Alimera Sciences was acquired on 16-Sep-2024.

  • Who acquired Alimera Sciences?

    Alimera Sciences was acquired by ANI Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »